FDA inspection
Kimberly Clark Corporation San Antonio Operations: FDA inspection ending Apr 3, 2003
FDA inspection 267405 · Voluntary Action Indicated (VAI) · San Antonio, TX
Key facts
| Inspection ID | 267405 |
|---|---|
| Firm | Kimberly Clark Corporation San Antonio Operations |
| FEI number | 1628278 |
| Address | 4702 Goldfield |
| City | San Antonio |
| State | TX |
| ZIP | 78218-4603 |
| Fiscal year | 2003 |
| Inspection end date | Apr 3, 2003 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance |
| Product type | Drugs, Food/Cosmetics |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data